Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab for Ambulatory Functions in Relapsing Multiple Sclerosis
NCT06629428Phase 1Recruiting
- Sponsor
- Georgia State University
- Start
- Nov 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ublituximab in multiple sclerosis (MS), sponsored by Georgia State University. Primary endpoints: Slip-fall at 48 weeks and Dynamic gait stability during slip at 48 weeks. Started Nov 2025; status: recruiting.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06629428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06629428.